Europe Cancer Biopsy Market Size and Growth 2032

Market Overview

The Europe Cancer Biopsy Market is projected to grow from USD 11,604.49 Million in 2025 to an estimated USD 21,662.41 Million by 2032, with a CAGR of 7.87% from 2025 to 2032.

Market expansion is driven by rising cancer incidence, wider use of precision oncology and growing adoption of minimally invasive liquid biopsy workflows across clinical settings.

Within Europe, Germany leads regional demand because of its strong oncology care infrastructure, advanced molecular diagnostics capacity and high spending on cancer screening and treatment.

Market Insights

• Western Europe accounted for 34.2% of Europe Cancer Biopsy Market revenue in 2025, supported by its strong concentration of oncology centers, advanced pathology networks, high healthcare spending, and broad use of image-guided and minimally invasive biopsy procedures.
• Consumables led product demand in 2025 with an estimated 38.6% share because recurring biopsy procedures require steady use of reagents, slides, needles and collection components.
• Tissue biopsies remained dominant by type with an estimated 71.4% share in 2025 because they remain standard for histopathology confirmation and biomarker testing.
• Leading companies shaping market competition include QIAGEN, Illumina, Inc., BD, F. Hoffmann-La Roche Ltd. and Guardant Health Inc.
• Key market trend centers on integrating next-generation sequencing, circulating tumor DNA analysis and automated sample preparation into routine cancer diagnosis pathways.

Market Segmentation Analysis

By product - Consumables anchor repeat demand across biopsy workflows

On the basis of product, the market is classified into Instrument, Kits, Consumables and Services. Consumables held the largest share, accounting for 38.6% in 2025. Growth reflects repeated use of needles, reagents, collection tubes, slides and pathology inputs across tissue and liquid biopsy procedures.

Demand remains strong because cancer testing volumes continue to rise in hospitals and diagnostic laboratories. Laboratories also prefer validated consumable platforms that improve sample integrity and workflow consistency. Key companies operating in this segment include QIAGEN, BD and Hologic, Inc.

By type - Tissue biopsies preserve frontline clinical relevance

On the basis of type, the market is classified into Tissue Biopsies and Liquid Biopsies. Tissue Biopsies dominated the market with 71.4% share in 2025. This leadership reflects their essential role in confirming malignancy, grading tumors and enabling immunohistochemistry and genomic profiling.

Clinicians continue to rely on tissue samples for definitive diagnosis in solid tumors, especially before therapy selection. Adoption remains high across tertiary hospitals and cancer centers with established pathology departments. Key companies operating in this segment include F. Hoffmann-La Roche Ltd., Illumina, Inc. and QIAGEN.

By application - Lung cancer leads biopsy demand across oncology use cases

On the basis of application, the market is classified into Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer and Other Cancers. Lung Cancer held the leading share at 19.8% in 2025.

Its dominance is linked to high disease burden, frequent need for molecular testing and growing use of repeat biopsies to monitor targeted therapy resistance. Both tissue and liquid biopsy demand are elevated in this application. Key companies operating in this segment include Guardant Health Inc., Biodesix and Illumina, Inc.

By end user - Hospitals remain primary purchasing and procedure centers

On the basis of end user, the market is classified into Hospitals, Diagnostic Centres and Research Institutes. Hospitals held the largest share, representing 56.3% in 2025. Their dominance stems from integrated oncology care, access to imaging-guided interventions and in-house pathology and surgical capabilities.

Hospitals also manage large patient volumes and complex cancer cases that require multidisciplinary diagnostics. Procurement favors broad biopsy portfolios with service support and assay reliability. Key companies operating in this segment include BD, F. Hoffmann-La Roche Ltd. and Hologic, Inc.

Key Growth Drivers

Rising cancer burden increases diagnostic testing volumes

Europe continues to face a heavy and rising cancer burden, which is increasing demand for tissue sampling, pathology review, and molecular biopsy testing as hospitals and specialized diagnostic centres handle more lung, breast, colorectal, and prostate cancer cases within formal diagnostic pathways.

Screening expansion is adding to this flow, with the European Commission aiming to offer breast, cervical, and colorectal screening to 90 percent of eligible EU citizens and also extending policy attention to lung and prostate cancers, which supports earlier referral and more biopsy procedures across the region.

The scale is evident in the numbers: IARC estimated 4,471,422 new cancer cases in Europe in 2022, including 557,532 breast, 538,262 colorectal, 484,306 lung, and 473,011 prostate cases, while Roche reported CHF 13.8 billion in Diagnostics sales in 2025 and said its diagnostics solutions touched 258 million lives, underlining how laboratories increasingly need dependable instruments, kits, and consumables to manage higher sample volumes without compromising turnaround time or analytical accuracy.

Precision oncology expands need for biomarker-led biopsy workflows

Precision oncology is reshaping cancer management across Europe. Oncologists increasingly depend on biopsy-derived molecular information to identify actionable mutations, select targeted therapies and monitor treatment resistance. This trend is increasing use of advanced assays in both tissue biopsies and liquid biopsies.

Next-generation sequencing, companion diagnostics and multi-marker panels now play a larger role in routine oncology practice. As therapeutic decisions become more genotype-specific, demand rises for sample quality, standardized pre-analytical handling and platforms that can support complex molecular testing at scale.

Pharmaceutical expansion in targeted therapies reinforces this shift. Large oncology developers now commercialize broad portfolios linked to biomarker testing, which encourages providers to strengthen biopsy infrastructure and integrate pathology with genomic analysis. This alignment between diagnostics and therapy selection remains a durable market growth engine.

Less invasive liquid biopsy adoption improves access and repeat testing

Liquid biopsy is gaining ground in Europe because it offers faster, less invasive sampling and is especially useful when repeat tissue collection is difficult in metastatic disease, frail patients, and cancers that need ongoing tracking of mutation evolution.

Clinical adoption is moving forward as assay sensitivity improves and expert guidance from ESMO states that validated, adequately sensitive plasma ctDNA assays have utility for identifying actionable mutations in advanced cancer and may be used in routine clinical practice with appropriate awareness of assay limits. This momentum is also visible in commercial-scale implementation, as Roche France, Foundation Medicine, and Gustave Roussy built an in-house liquid biopsy partnership around FoundationOne Liquid CDx, which analyzes more than 300 cancer-related genes, and Gustave Roussy noted that genomic profiling is indicated for up to 200,000 patients every year in France, showing why laboratories and cancer centres are investing in workflows that shorten reporting time and make repeatable monitoring more practical for therapy selection, minimal residual disease surveillance, and relapse detection.

Key Trends & Opportunities

Trend-

Molecular profiling moves deeper into routine oncology care

Europe Cancer Biopsy Market is seeing stronger alignment between biopsy procedures and comprehensive molecular profiling. Tissue samples are increasingly processed not only for histology but also for genomic and proteomic analysis. This shift raises demand for high-quality collection systems, extraction kits and sequencing-compatible workflows.

Laboratory modernization is supporting this trend. More cancer centres are adopting automated sample preparation and digital pathology tools to improve throughput and reduce pre-analytical variability. One important supporting signal is the continued rise in installed next-generation sequencing capacity across major European reference laboratories and oncology networks.

Liquid biopsy expands from advanced disease into monitoring pathways

Liquid biopsy adoption is moving beyond late-stage mutation detection into longitudinal monitoring, recurrence assessment and therapy response tracking. Clinicians value its lower procedural burden and ability to capture dynamic tumor changes over time. This makes the technology especially relevant in lung, colorectal and breast cancer management.

Commercial developers are refining assay sensitivity, panel breadth and turnaround time to meet routine clinical needs. As evidence grows, healthcare providers are evaluating how liquid biopsy can complement tissue biopsies rather than replace them. This hybrid diagnostic model is becoming a defining direction for the market.

Opportunity -

Expand access through decentralized testing networks

A major opportunity lies in extending advanced cancer biopsy services beyond large academic hospitals into regional hospital systems and community diagnostic networks. Europe has meaningful variation in oncology testing access, which creates room for providers offering standardized instruments, easy-to-use kits and central-lab service support.

Companies that simplify logistics, stabilize samples during transport and integrate software for results interpretation can improve adoption in less concentrated healthcare settings. This opportunity is particularly strong where referral patterns support hub-and-spoke diagnostics and where health systems aim to reduce time to treatment initiation.

Build value through companion diagnostics and service models

Another strong opportunity comes from linking biopsy platforms with companion diagnostics, laboratory services and oncology partnerships. As targeted therapies expand, providers that pair assays with clinically actionable insights can strengthen their position with hospitals, pharmaceutical companies and specialized cancer centres.

Service-led models also create recurring revenue through testing support, assay validation and workflow optimization. In Europe, purchasers increasingly evaluate not only device performance but also quality systems, training and reimbursement readiness. Vendors that address these factors can capture share in both tissue and liquid biopsy segments.

Key Challenges

Challenge -

Reimbursement and evidence requirements vary across markets

Europe remains a fragmented market with significant variation in reimbursement rules, health technology assessment standards and clinical pathway adoption. This creates uneven uptake for advanced biopsy platforms, especially liquid biopsy tests that require strong clinical utility evidence before broader payer acceptance.

Manufacturers must often navigate country-specific approval expectations, coding structures and procurement processes. These differences can slow commercialization, delay routine use and increase market entry costs even when technologies show clear technical value in oncology diagnostics.

Sample quality and workflow standardization remain critical barriers

Biopsy performance depends heavily on collection quality, storage conditions and laboratory processing consistency. Tissue samples may be limited or degraded, while liquid biopsy assays can be affected by low tumor DNA abundance and pre-analytical variability. These factors can influence sensitivity and reporting confidence.

Healthcare providers therefore demand rigorous validation, operator training and integrated quality control. Vendors that fail to deliver reproducible workflows may face slower adoption, particularly in decentralized settings where technical expertise and infrastructure vary across institutions.

Regional Analysis

Western Europe - 34.2%

Western Europe holds the largest share of the Europe Cancer Biopsy Market due to its strong concentration of oncology centers, advanced pathology networks, high healthcare spending, and broad use of image-guided and minimally invasive biopsy procedures. Germany, France, the Netherlands, Belgium, Austria, Switzerland, and Luxembourg are the main contributors. Germany and France, in particular, anchor demand because of their large patient pools and strong hospital-based cancer diagnostics ecosystems. Higher per-capita health expenditure in countries such as Germany and Switzerland also supports faster adoption of advanced biopsy needles, vacuum-assisted systems, liquid biopsy workflows, and molecular pathology-linked biopsy testing.

Southern Europe - 23.1%

Southern Europe represents the second-largest share, supported by sizable populations and steady cancer diagnosis volumes across Italy, Spain, Portugal, and Greece. Italy and Spain account for most of the regional demand, driven by large public hospital systems, increasing oncology case detection, and expanding use of breast, gastrointestinal, prostate, and lung cancer biopsy procedures. However, the market remains somewhat constrained versus Western Europe because screening participation and diagnostic throughput are less uniform across countries, which creates variation in biopsy volumes and access to premium devices.

Northern Europe - 17.4%

Northern Europe commands a strong share despite its smaller population base because countries such as the UK, Ireland, Denmark, Sweden, Norway, and Finland have highly organized cancer pathways, good screening participation, and well-developed diagnostic services. OECD data show that countries such as Denmark, Sweden, Finland, and the Netherlands achieve some of the strongest screening participation levels in Europe, which supports early lesion detection and steady biopsy demand. The UK is the largest single contributor in this subregion, while the Nordics contribute disproportionately through high-value adoption of precision diagnostics and structured referral systems.

Central Europe - 14.6%

Central Europe accounts for a meaningful share, led by Poland, Czechia, Hungary, Slovakia, and Slovenia. The region benefits from improving cancer care investment, growing modernization of diagnostic labs, and gradual convergence in cancer spending with Western Europe. Poland is the largest market in this cluster because of its population scale and expanding oncology care capacity. Still, market share remains below Western and Southern Europe because screening coverage, hospital funding depth, and access to premium biopsy technologies are still less consistent across the region.

Eastern Europe - 10.7%

Eastern Europe holds the smallest share, though it remains an important growth zone for the Europe Cancer Biopsy Market. Countries including Romania, Bulgaria, Croatia, and the Baltic states are seeing rising cancer care needs, but market development is moderated by lower per-capita health expenditure, lower screening participation in several markets, and uneven pathology and oncology infrastructure. OECD evidence shows that some Eastern European countries continue to trail broader European averages in screening uptake and spending, which limits present market size even as long-term demand strengthens.

Market Segmentations

• Product
  • Instrument
  • Kits
  • Consumables
  • Services
• Type
  • Tissue Biopsies
  • Liquid Biopsies
• Application
  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Esophagus Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Other Cancers
• End User
  • Hospitals
  • Diagnostic Centres
  • Research Institutes

• By Geography

Competitive Landscape

Competition in the Europe Cancer Biopsy Market is marked by strong innovation in molecular assays, liquid biopsy platforms and integrated pathology workflows. Leading companies focus on expanding assay sensitivity, sample preparation efficiency and biomarker coverage to support precision oncology use cases across solid tumors.

Product strategy increasingly centers on pairing instruments, kits and consumables with software, laboratory services and companion diagnostic capabilities. Companies also pursue distribution partnerships with hospital networks, diagnostic laboratories and regional channel partners to widen market access and improve service responsiveness.

Competitive intensity remains high as established diagnostics firms compete with specialized oncology testing companies. Differentiation depends on analytical performance, regulatory readiness, clinical evidence, reimbursement positioning and the ability to support both centralized and decentralized testing environments.

Key Player Analysis

• QIAGEN
• Illumina, Inc.
• ANGLE plc
• BD
• Biodesix
• Lucence Health Inc.
• Myriad Genetics, Inc.
• Hologic, Inc.
• Oncimmune Holdings PLC
• F. Hoffmann-La Roche Ltd.
• Guardant Health Inc.
• Epigenomics AG

Recent Developments

• In May 2025, NHS England began rolling out a liquid biopsy blood test for lung cancer patients, calling it the first national health system deployment of the approach at that scale. The announcement said the test can help some patients receive targeted treatment up to two weeks earlier and may reduce the need for additional invasive tissue biopsies, making it a significant clinical innovation in Europe’s cancer biopsy pathway.
• In July 2025, Barcelona-based Flomics Biotech joined the Eurostars-funded LUMINA project to develop a platform for detecting lung cancer recurrence through liquid biopsy and artificial intelligence. The consortium includes Uppsala University in Sweden and Oncodia AB, and the project is designed to combine circulating RNA and DNA biomarkers with predictive algorithms to identify minimal residual disease before relapse becomes clinically visible, which gives the collaboration strong translational relevance for European oncology diagnostics.
• In December 2025, Guardant Health and Rome’s Policlinico Gemelli launched FPG 360, an in-house liquid biopsy testing service in Italy based on Guardant360 CDx technology. The reports said the service is one of the first dedicated liquid-biopsy facilities housed within an Italian hospital system and is intended to let cancer patients access comprehensive genomic profiling locally instead of sending samples abroad, strengthening both routine care and clinical research.
• In March 2026, France-based Koelis announced new products at EAU 2026 in London to improve MRI-ultrasound fusion biopsy workflows in prostate cancer. The company said its updates include AI-assisted 3D image processing and workflow improvements intended to make transperineal targeted biopsy more efficient while linking biopsy more seamlessly to focal therapy, making this a notable product-led advance in Europe’s prostate cancer intervention market.